BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.55 Million EUR | -67.4% |
| 2022 | 29.32 Million EUR | 48.31% |
| 2021 | 19.77 Million EUR | -20.39% |
| 2020 | 24.83 Million EUR | 10.91% |
| 2019 | 22.39 Million EUR | -13.05% |
| 2018 | 25.75 Million EUR | 2.3% |
| 2017 | 25.17 Million EUR | -34.76% |
| 2016 | 38.58 Million EUR | -23.42% |
| 2015 | 50.38 Million EUR | 108.18% |
| 2014 | 24.2 Million EUR | 88.92% |
| 2013 | 12.81 Million EUR | -11.15% |
| 2012 | 14.41 Million EUR | -4.22% |
| 2011 | 15.05 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 9.39 Million EUR | -1.71% |
| 2024 Q2 | 9.39 Million EUR | 0.0% |
| 2023 Q4 | 9.55 Million EUR | 0.0% |
| 2023 Q3 | 9.55 Million EUR | -8.02% |
| 2023 FY | 9.55 Million EUR | -67.4% |
| 2023 Q1 | 10.39 Million EUR | -64.56% |
| 2023 Q2 | 10.39 Million EUR | 0.0% |
| 2022 Q4 | 29.32 Million EUR | 0.0% |
| 2022 FY | 29.32 Million EUR | 48.31% |
| 2022 Q2 | 11.73 Million EUR | 0.0% |
| 2022 Q3 | 29.32 Million EUR | 149.95% |
| 2021 Q2 | 14.32 Million EUR | 0.0% |
| 2021 Q4 | 19.77 Million EUR | 0.0% |
| 2021 FY | 19.77 Million EUR | -20.39% |
| 2020 FY | 24.83 Million EUR | 10.91% |
| 2020 Q4 | 24.83 Million EUR | 0.0% |
| 2020 Q2 | 22.64 Million EUR | 0.0% |
| 2019 Q4 | 22.39 Million EUR | 0.0% |
| 2019 Q2 | 27.93 Million EUR | 0.0% |
| 2019 FY | 22.39 Million EUR | -13.05% |
| 2018 Q2 | 24.43 Million EUR | 0.0% |
| 2018 FY | 25.75 Million EUR | 2.3% |
| 2018 Q4 | 25.75 Million EUR | 0.0% |
| 2017 Q4 | 25.17 Million EUR | 0.0% |
| 2017 FY | 25.17 Million EUR | -34.76% |
| 2017 Q2 | 29.84 Million EUR | 0.0% |
| 2016 Q2 | 43.38 Million EUR | 0.0% |
| 2016 Q4 | 38.58 Million EUR | 0.0% |
| 2016 FY | 38.58 Million EUR | -23.42% |
| 2015 Q2 | 51.3 Million EUR | 0.0% |
| 2015 Q4 | 50.38 Million EUR | 0.0% |
| 2015 FY | 50.38 Million EUR | 108.18% |
| 2014 Q4 | 24.2 Million EUR | 86.59% |
| 2014 Q3 | 12.97 Million EUR | 0.0% |
| 2014 FY | 24.2 Million EUR | 88.92% |
| 2013 FY | 12.81 Million EUR | -11.15% |
| 2013 Q4 | 12.81 Million EUR | 0.0% |
| 2012 FY | 14.41 Million EUR | -4.22% |
| 2011 FY | 15.05 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 35.017% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 97.077% |
| Adocia SA | 24.95 Million EUR | 61.697% |
| Aelis Farma SA | 26.28 Million EUR | 63.628% |
| Biophytis S.A. | 11.93 Million EUR | 19.915% |
| Advicenne S.A. | 12.4 Million EUR | 22.955% |
| genOway Société anonyme | 31.84 Million EUR | 69.98% |
| IntegraGen SA | 8 Million EUR | -19.482% |
| Medesis Pharma S.A. | 1.92 Million EUR | -396.227% |
| Neovacs S.A. | 47.53 Million EUR | 79.89% |
| NFL Biosciences SA | 3.97 Million EUR | -140.743% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 35.901% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -155.126% |
| Sensorion SA | 46.49 Million EUR | 79.44% |
| Theranexus Société Anonyme | 7.23 Million EUR | -32.072% |
| TME Pharma N.V. | 2.49 Million EUR | -283.741% |
| Valbiotis SA | 33.24 Million EUR | 71.249% |
| TheraVet SA | 7.53 Million EUR | -26.875% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 72.901% |
| argenx SE | 4.11 Billion EUR | 99.768% |
| Celyad Oncology SA | 16.28 Million EUR | 41.291% |
| DBV Technologies S.A. | 165.65 Million USD | 94.229% |
| Galapagos NV | 4.35 Billion EUR | 99.781% |
| Genfit S.A. | 173.87 Million EUR | 94.502% |
| GeNeuro SA | 6.31 Million EUR | -51.42% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 79.952% |
| Innate Pharma S.A. | 184.19 Million EUR | 94.81% |
| Inventiva S.A. | 69.13 Million EUR | 86.174% |
| MaaT Pharma SA | 42.93 Million EUR | 77.734% |
| MedinCell S.A. | 36.94 Million EUR | 74.129% |
| Nanobiotix S.A. | 93.89 Million EUR | 89.82% |
| Onward Medical N.V. | 43.62 Million EUR | 78.09% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 91.058% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 88.328% |
| Oxurion NV | 6.55 Million EUR | -45.939% |
| Pharming Group N.V. | 426.33 Million EUR | 97.758% |
| Poxel S.A. | 4.82 Million EUR | -98.196% |
| GenSight Biologics S.A. | 9.08 Million EUR | -5.194% |
| Transgene SA | 45.21 Million EUR | 78.86% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.502% |
| UCB SA | 15.53 Billion EUR | 99.938% |
| Valneva SE | 469.39 Million EUR | 97.964% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 68.993% |